Arcoma AB
The answer first
Does Arcoma beat the market?
No, Arcoma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 74% of Nordic stocks
- Quality81
- Value75
- Trend33
No. 30 of 195 in healthcare
Expectations in the price
Low expectations
For the share to return about 9% a year from today's price, it is enough that the cash Arcoma keeps shrinks about 3% a year for 10 years.
Max for seven days
Follow Arcoma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 17 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Arcoma
Your first answer is free, no account needed.
Do you own Arcoma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Arcoma and a few more. Free, no card.
Super Stock+45.9%In short
- Arcoma has risen 4.4% over the past year, including dividends.
- Overall, Arcoma ranks better than 74% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 72.5%. The price is 70.2% below its peak now.
What do analysts think of Arcoma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 74% of Nordic stocks.
No. 30 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 50 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns1.30
- Return on equityProfit divided by equity+6.2%
- Cash conversionOperating cash flow divided by profit2.49
The ranking is built on equity ratio, ROA and how steadily profit grows.
High Low price: you pay little for what the company earns and owns.
No. 16 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity1.4
- P/SPrice divided by sales0.9
- P/EPrice divided by earnings22.2
- P/CFPrice divided by operating cash flow8.9
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 103 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−9.9%
- 6 months−18.6%
- 9 months−8.0%
- 12 months+4.4%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Arcoma
One fund we follow owns Arcoma. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Arcoma
Arcoma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 31 employees.
Arcoma AB (publ) develops, produces, and provides radiology solutions and digital x-ray systems in Sweden and internationally. The company offers solutions for x-ray systems covering radiological applications and general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. It also provides x-ray detectors; video bank; and accessories for x-ray equipment comprising live camera, advanced remote control, form pad, hand control, compression belt, detector holder, foot control, lateral armrest, patient handgrip, mattress, scatter correction software, battery charger, battery pack, and stitching screen.


See the full analysis of Arcoma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card